Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure Management
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 608
- 试验地点
- 4
- 主要终点
- Perceptions towards role of systemic inflammation in identification, treatment, management of ASCVD+CKD and HF
研究概览
简要总结
This is a survey-based study conducted among cardiologists and nephrologists treating people with Atherosclerotic Cardiovascular Disease (ASCVD), Heart Failure (HF) and Chronic Kidney Disease (CKD). Study participants will be recruited to complete self-administered online survey. The purpose of this research is to gather real-world evidence related to attitudes around systemic inflammation and specifically the awareness, perception, drivers and barriers, and use of hsCRP in clinical practice to identify systemic inflammation in people with ASCVD+CKD and HF.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed consent obtained before any study related activities (study-related activities are any procedure related to recording of data according to the protocol).
- •Male or female, age above 18 years at the time of signing informed consent.
- •Is a nephrologist or cardiologist. Cardiologists may be a mix of Interventional Cardiology, Heart Failure (HF) Specialist, General Cardiology, Preventative Cardiology, Cardiac Electrophysiology, Cardio-Oncology or Echocardiography (India only).
- •Has been in specialty practice greater than or equal to 3 years.
- •If cardiologist, sees at least 15 people with Atherosclerotic Cardiovascular Disease (ASCVD) with or without Chronic Kidney Disease (CKD) per month.
- •If nephrologist, sees at least 20 people with ASCVD and CKD per month.
排除标准
- •Previous participation in this study. Participation is defined as having given informed consent in this study.
- •Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- •If nephrologist, is only using dialysis to treat people with ASCVD and CKD.
- •Does not meet inclusion criteria requirements.
研究组 & 干预措施
Nephrologist Group
This group includes nephrologists treating people with ASCVD and CKD.
干预措施: No treatment given (Other)
Cardiologist Group
This group includes cardiologist treating people with ASCVD and CKD.
干预措施: No treatment given (Other)
结局指标
主要结局
Perceptions towards role of systemic inflammation in identification, treatment, management of ASCVD+CKD and HF
时间窗: At the time of survey response (Day 1)
Multi-select from a defined list; 7-point Likert scale where 1=Not at all Important and Single-select from a defined list; Numerical; 7=Extremely Important; 7-point Likert scale where 1=Strongly Disagree and 7=Strongly Agree. Cardiologists and nephrologists' perceptions towards the role of systemic inflammation in the identification, treatment and management of people with Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease (ASCVD+CKD) and Heart Failure (HF)
次要结局
未报告次要终点